Abstract 141P
Background
Microsatellite instability-high (MSI-H) is a well-known favorable prognostic marker in localized colorectal cancer (CRC) patients, mainly due to local anti-tumor immunity of cytotoxic T cells. The tumor-induced systemic inflammation is also proven to be responsible for pro-tumor immunity. Despite the importance of tumor microenvironment, the relationships between MSI status, systemic inflammation, and their prognostic effects in CRC patients have not been widely studied.
Methods
We retrospectively analyzed a total of 1130 patients who had diagnosed as stage I to III CRC and had surgical resection from Jan 2007 to Oct 2016 at Gil Medical Center in South Korea. MSI status was evaluated by polymerase-chain reaction (PCR) of mononucleotide repeats. Neutrophil-lymphocyte ratio (NLR), from the blood cell count drawn before any treatment, was used to represent systemic inflammation. Univariable and multivariable analysis were performed with Cox’s proportional hazard model to identify prognostic factors in localized CRC patients.
Results
Among 1130 patients of stage I to III CRC, 84 (7.4%) patients had MSI-H CRC, and the majority of MSI-H CRCs were found in stage II patients (12.2%, n=46/378). MSI-H was significantly associated with high NLR (20.2% vs 7.4%, p<0.001) as well as right-sided (67.4% vs 20.9%, p<0.001), poorly differentiated (17.4% vs 2.8%, p<0.001), less perineural invasion (11.6% vs 22.4%, p=0.020), and low BMI (5.8% vs 14.3%, p=0.028). Combining MSI and NLR, MSS/NLR≥5 group showed worst PFS and OS consistently throughout stage I to III (p=0.017). Interestingly, MSI-H/NLR≥5 group showed worse PFS and OS than MSS/NLR<5 group in stage II patients (p=0.006). In multivariable analysis, MSS/NLR≥5 group was related significantly with poor PFS (HR 4.19, 95% CI 1.37-12.83, p=0.012), and showed a trend toward poor OS (HR 4.42, 95% CI 0.84-23.11, p=0.079).
Conclusions
MSI-H was significantly associated with high NLR, and its prognostic effect outweighed that of MSI-H, especially in stage II CRC. Therefore, we should consider more about factors of tumor microenvironment such as high NLR, as one of criteria to classify high-risk stage II CRC, which needs adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
186P - Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials
Presenter: Marco Tagliamento
Session: Poster session 01
187P - Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 01
188P - The landscape of SMARCA2 genomic alterations in Chinese cancer patients
Presenter: Chen Jiaqi
Session: Poster session 01
189P - Design and enrollment for a classifier development study for a blood-based multi-cancer early detection (MCED) test
Presenter: Christopher Douville
Session: Poster session 01
190P - Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma
Presenter: John Paul Shen
Session: Poster session 01
191P - Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment
Presenter: Kassandra Bisson, Brandon Sheffield
Session: Poster session 01
192P - Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
Presenter: Hussein Sweiti
Session: Poster session 01
194P - Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
Presenter: Dominik Barth
Session: Poster session 01
195P - Identification of biomarkers associated with checkpoint inhibitor pneumonitis based on serum proteomic approach and construction of an online interactive visual prediction model
Presenter: Xiaohui Jia
Session: Poster session 01
196P - Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts
Presenter: Yanjun Xu
Session: Poster session 01